TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in…
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023…
The Company Holds a US Patent for the Same Treatment FREMONT, CA, Oct. 09, 2023…
Company to Discuss Upcoming Briquilimab Clinical Studies in Both Chronic Spontaneous Urticaria and Chronic Inducible…
Company to Discuss Upcoming Briquilimab Clinical Studies in Both Chronic Spontaneous Urticaria and Chronic Inducible…
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE…
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE…
Topline results expected in 2H 2024 CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) — MBX…
Topline results expected in 2H 2024 CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) — MBX…
Mr. Garner brings over 25 years of pharmaceutical industry experience THE WOODLANDS, Texas, Oct. 09,…
Mr. Garner brings over 25 years of pharmaceutical industry experience THE WOODLANDS, Texas, Oct. 09,…
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical…
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical…
Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual Film Reaffirms…
Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual Film Reaffirms…
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1…
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1…
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…